Carregant...
New survival standards for advanced melanoma
The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing th...
Guardat en:
| Publicat a: | Br J Cancer |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7188675/ https://ncbi.nlm.nih.gov/pubmed/32063602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0738-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|